Fig. 5
From: p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer
TMEM16A expression is a predictive marker for the efficacy of cisplatin and BI-D1870 combination in vitro. (A) Combination index (CI) values of indicated cell lines treated with increasing concentrations of cisplatin and BI-D1870 at a fixed ratio. CI less than 1.0 (green) indicates synergy, CI between 1.0 and 2.0 (yellow) indicates additivity, and CI greater than 2.0 (grey) indicates antagonism. This experiment was done twice. Data shown is the result of one experiment. (B-E) Viability of indicated cell lines treated with increasing concentrations of cisplatin with and without BI-D1870. Graphs from one representative experiment are shown. Comparisons are made between groups representing viability of cells with and without BI-D1870 within cisplatin treatments. Statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparison test. *p < 0.05, **p 0.001, ***p < 0.0001